---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005498"
form_type: "8-K"
ticker: "EDAP"
cik: "0001041934"
company_name: "EDAP TMS SA"
filed_at: "2026-08-13T20:02:17+00:00"
generated_at: "2026-08-13T20:03:23.883425+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FocalTherics Q2 revenue up 39% to $13.2M; net loss widens; $40M offering

## Summary
- Revenue $13.2M, +39% YoY; U.S. procedure volume +47%; 13 Focal One systems sold vs 9.
- Gross margin 55.6% vs 51.1%; operating loss $8.0M vs $6.6M; net loss $14.4M ($0.38/sh) vs $6.4M.
- ESWL and Distribution reclassified as discontinued operations; HIFU now only continuing ops; cash $21.5M.
- FY2026 revenue guidance reaffirmed $50-54M (34-45% growth); $40M public offering expected to close Aug 14.
- Launched first commercial Focal One Endometriosis program in Europe; installed base 184 (96 U.S.).

## SEC filing metadata
- accession: 0001171843-26-005498
- form_type: 8-K
- ticker: EDAP
- cik: 0001041934
- company_name: EDAP TMS SA
- filed_at: 2026-08-13T20:02:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041934/000117184326005498/0001171843-26-005498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041934/000117184326005498/f8k_081326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005498
- JSON: https://secwatch.observer/filing/0001171843-26-005498.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005498.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.